Company: NCEL
Filing Date: 2025-02-05
Form Type: F-3
Source: 0001213900-25-010223
Chunk: 56

Company: NewcelX Ltd.
Filing Date: 2025-02-05
Form: F-3
Chunk 56
---
 any other current or future product candidate, it will likely incur significant sales, marketing and outsourced manufacturing expenses, as well as continued research and development expenses. Furthermore, in the period following this prospectus, it expects to incur additional costs associated with operating as a public company, which Kadimastem estimates will be at least several hundred thousand dollars annually. As a result, Kadimastem expects to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing pharmaceutical products, Kadimastem is unable to predict the extent of any future losses or when it will become profitable, if at all.

Furthermore, in addition to such operating expenses, Kadimastem expects to incur additional costs associated with operating as a public company subject to the rules and regulations of the SEC, which it estimates will be at least one million dollars annually. As a result, Kadimastem expects to continue to incur significant and increasing operating losses for the foreseeable future. Because of the numerous risks and uncertainties associated with developing drug substances and product candidates, Kadimastem is unable to predict the extent of any future losses or when Kadimastem will become profitable, if at all.

Kadimastem expects to continue to incur significant losses until Kadimastem are able to commercialize Kadimastem’s product candidates, which it may not be successful in achieving. Kadimastem anticipate that Kadimastem’s expenses will increase substantially if and as we:

| ● | continue the research and                            
 development of Kadimastem’s product candidates;      |
| ● | expand the scope of Kadimastem’s                     
 current clinical studies for its product candidates; |

| ● | seek regulatory and marketing                                                              
 approvals for Kadimastem’s product candidates that successfully complete clinical studies; |

<div align='center'>37</div>

| ● | establish a sales, marketing,                                                                                                    
 and distribution infrastructure to commercialize Kadimastem’s product candidates;                                                |
| ● | seek to identify, assess,                                                                                                        
 acquire, license, and/or develop other product candidates and subsequent generations of Kadimastem’s current product candidates; |
| ● | seek to maintain, protect,                                                                                                       
 and expand Kadimastem’s intellectual property portfolio;                                                                         |
| ● | seek to attract and retain                                                                                                       
 skilled personnel; and                                                                                                           |
| ● | create additional infrastructure                                                                                                 
 to support Kadimastem’s operations as a public company and Kadimastem